1-3 of 3
Glenn Heller
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation

Manpreet Bariana, Elena Cassella, Janice Rateshwar, Samedy Ouk, Hsiou-Chi Liou, Claudia Heller, Iriana Colorado, Rena Feinman, Ali Makhdoom, David S. Siegel, Glenn Heller, Andrea Tuckett, Patrizia Mondello, Johannes L. Zakrzewski
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (12): 1798–1809.
https://doi.org/10.1158/1535-7163.MCT-22-0257
Published: 02 December 2022
View article titled, Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation
Open the PDF for Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation in another window
Includes: Supplementary data
Journal Articles

Circulating tumor cells as prognostic biomarkers in patients with metastatic prostate cancer

Daniel Danila, Glenn Heller, Margaret Leversha, Hans Lilja, Rita Gonzalez-Espinoza, Aseem Anand, Steve Larson, Lawrence Schwartz, Martin Fleisher, Howard Scher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C51.
Published: 01 November 2007
View article titled, Circulating tumor cells as prognostic biomarkers in patients with metastatic prostate cancer
Journal Articles

PCK3145, a novel multitargeted signalling agent for the treatment of castrate metastatic prostate cancer (CMPC)

Susan Slovin, Helene Dulude, Chandra Panchal, Maroussia Czarny, Tracy Curley, Michael Morris, Dana Rathkopf, Lawrence Schwartz, Glenn Heller, Howard Scher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A11.
Published: 01 November 2007
View article titled, PCK3145, a novel multitargeted signalling agent for the treatment of castrate metastatic prostate cancer (CMPC)